Demis Hassabis stated that within the next 10–15 years artificial intelligence will usher in a “new golden era of discovery,” forecasting breakthroughs in personalized treatments for major diseases, cleaner energy solutions and expanded space exploration capabilities.

The 2023 merger of Google Brain and DeepMind created a unified research organization powering advanced models like Gemini, while DeepMind’s AlphaFold solution to the protein folding challenge underpins Isomorphic Labs’ efforts to accelerate drug discovery by up to 1,000 times and advance preclinical cancer trials.

A two-stage earnings-based DCF model using EPS of $9.17, an 11% discount rate, 25.20% growth for 10 years and a 4% terminal growth rate produces an intrinsic value of $286.41 per share versus the current $305.72 market price, indicating a 6.74% margin of safety shortfall.